Current problems of in vivo developmental neurotoxicity tests and a new in vivo approach focusing on each step of the developing central nervous system

Congenital Anomalies

Volumn 52, Issue 3, 2012, Pages 129-139

  Kuwagata, Makiko ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 bromo 2 deoxyuridine; Developmental neurotoxicity test; Fetal brain observation; New in vivo approach; Valproic acid

Indexed keywords

ACRYLAMIDE; ALDICARB; ALLETHRIN; BENOMYL; BROXURIDINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; COLCHICINE; DEMECOLCINE; DIAZEPAM; DIELDRIN; DIETHYLSTILBESTROL; DIMPYLATE; FLUOROURACIL; HALOPERIDOL; HALOTHANE; HEPTACHLOR; HYDROXYUREA; LINDANE; MANEB; METHADONE; METHANOL; METRIFONATE; NALOXONE; NALTREXONE; NICOTINE; THALIDOMIDE; TRIAMCINOLONE; UNINDEXED DRUG; VALPROIC ACID;

AUTISM; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; DEVELOPMENTAL NEUROTOXICITY TEST; DRUG EXPOSURE; GESTATION PERIOD; HISTOPATHOLOGY; HYPERACTIVITY; IN VIVO STUDY; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REVIEW; SYNAPTOGENESIS; TOXICITY TESTING;

ANIMALS; ANIMALS, NEWBORN; CELL DIFFERENTIATION; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM; HUMANS; MODELS, ANIMAL; NERVE NET; NERVOUS SYSTEM DISEASES; NEURAL STEM CELLS; NEUROTOXICITY SYNDROMES;

ANIMALIA; MAMMALIA;

EID: 84865554859     PISSN: 09143505     EISSN: 17414520     Source Type: Journal    
DOI: 10.1111/j.1741-4520.2012.00376.x     Document Type: Review

References (51)

1. Artlich A, Moller J, Tschakaloff A, Schwinger E, Kruse K, Gortner L. 1994. Teratogenic effects in a case of maternal treatment for acute myelocytic leukaemia - neonatal and infantile course. Eur J Pediatr 153:488-491.
2. Bacon Y, Ooi A, Kerr S etal. 2004. Screening for novel ENU-induced rhythm, entrainment and activity mutants. Genes Brain Behav 3:196-205.
3. Battino D, Binelli S, Caccamo ML etal. 1992. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurol Scand 85:204-207.
4. Bayer SA, Altman J. 1995. Neurogenesis and neuronal migration. In: Paxinos G, editor. The rat nervous system, Second edn. Australia: Acaemic Press Inc. p 1041-1098.
5. Chaturvedi RK, Shukla S, Seth K etal. 2006. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Neurobiol Dis 22:421-434.
6. Christianson AL, Chesler N, Kromberg JG. 1994. Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Dev Med Child Neurol 36:361-369.
7. Crofton KM, Makris SL, Sette WF, Mendez E, Raffaele KC. 2004. A qualitative retrospective analysis of positive control data in developmental neurotoxicity studies. Neurotoxicol Teratol 26:345-352.
8. Crofton KM, Mundy WR, Lein PJ etal. 2011. Developmental neurotoxicity testing: recommendations for developing alternative methods for the screening and prioritization of chemicals. ALTEX 28:9-15.
9. Dellu-Hagedorn F. 2005. Spontaneous individual differences in cognitive performances of young adult rats predict locomotor response to amphetamine. Neurobiol Learn Mem 83:43-47.
10. Dowling AL, Iannacone EA, Zoeller RT. 2001. Maternal hypothyroidism selectively affects the expression of neuroendocrine-specific protein A messenger ribonucleic acid in the proliferative zone of the fetal rat brain cortex. Endocrinology 142:390-399.
11. Fiore M, Aloe L, Westenbroek C, Amendola T, Antonelli A, Korf J. 2001. Bromodeoxyuridine and methylazoxymethanol exposure during brain development affects behavior in rats: consideration for a role of nerve growth factor and brain derived neurotrophic factor. Neurosci Lett 309:113-116.
12. Gospe SM Jr, Zhou SS. 1998. Toluene abuse embryopathy: longitudinal neurodevelopmental effects of prenatal exposure to toluene in rats. Reprod Toxicol 12:119-126.
13. Ingram JL, Peckham SM, Tisdale B, Rodier PM. 2000. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol Teratol 22:319-324.
14. Katayama K, Ueno M, Yamauchi H, Nagata T, Nakayama H, Doi K. 2005. Ethylnitrosourea induces neural progenitor cell apoptosis after S-phase accumulation in a p53-dependent manner. Neurobiol Dis 18:218-225.
15. Keays DA, Nolan PM. 2003. N-ethyl-N-nitrosourea mouse mutants in the dissection of behavioural and psychiatric disorders. Eur J Pharmacol 480:205-217.
16. Kim SK, Moon HJ, Park JH etal. 2007. The maintenance of individual differences in the sensitivity of acute and neuropathic pain behaviors to electroacupuncture in rats. Brain Res Bull 74:357-360.
17. Kolb B, Pedersen B, Ballermann M, Gibb R, Whishaw IQ. 1999. Embryonic and postnatal injections of bromodeoxyuridine produce age-dependent morphological and behavioral abnormalities. J Neurosci 19:2337-2346.
18. Kuwagata M, Nagao T. 1998. Behavior and reproductive function of rat male offspring treated prenatally with 5-bromo-2′-deoxyuridine. Reprod Toxicol 12:541-549.
19. Kuwagata M, Takashima T, Nagao T. 1998. A comparison of the in vivo and in vitro response of rat embryos to 5-fluorouracil. J Vet Med Sci 60:93-99.
20. Kuwagata M, Saito Y, Usumi K, Ono H, Nagao T. 2001. Disruption of brain development in male rats exposed prenatally to 5-bromo-2′-deoxyuridine. Congenit Anom (Kyoto) 41:312-320.
21. Kuwagata M, Muneoka KT, Ogawa T, Takigawa M, Nagao T. 2004. Locomotor hyperactivity following prenatal exposure to 5-bromo-2′-deoxyuridine: neurochemical and behavioral evidence of dopaminergic and serotonergic alterations. Toxicol Lett 152:63-71.
22. Kuwagata M, Ogawa T, Nagata T, Shioda S. 2007. The evaluation of early embryonic neurogenesis after exposure to the genotoxic agent 5-bromo-2′-deoxyuridine in mice. Neurotoxicology 28:780-789.
23. Kuwagata M, Ogawa T, Shioda S, Nagata T. 2009. Observation of fetal brain in a rat valproate-induced autism model: a developmental neurotoxicity study. Int J Dev Neurosci 27:399-405.
24. Kuwagata M, Ogawa T, Muneoka K, Shioda S. 2011. Hyperactivity induced by prenatal BrdU exposure across several experimental conditions. Congenit Anom (Kyoto) 51:177-182.
25. Laposa RR, Henderson JT, Xu E, Wells PG. 2004. ATM-null mice exhibit enhanced radiation-induced birth defects and a hybrid form of embryonic programmed cell death indicating a teratological suppressor function for ATM. FASEB J 18:896-898.
26. Londei T, Misto R, Vismara C, Leone VG. 1995. Congenital brain damage spares the basic patterns of parental behavior in affected mice. Brain Res 677:61-68.
27. Miller MW, Nowakowski RS. 1988. Use of bromodeoxyuridine-immunohistochemistry to examine the proliferation, migration and time of origin of cells in the central nervous system. Brain Res 457:44-52.
28. Morris SM. 1991. The genetic toxicology of 5-bromodeoxyuridine in mammalian cells. Mutat Res 258:161-188.
29. Nagao T, Sato M, Kuwagata M, Saito Y. 1997. Effects of prenatal exposure to 5-bromo-2′-deoxyuridine on reproductive function in male mouse offspring. Reprod Toxicol 11:663-673.
30. Narita M, Oyabu A, Imura Y etal. 2010. Nonexploratory movement and behavioral alterations in a thalidomide or valproic acid-induced autism model rat. Neurosci Res 66:2-6.
31. Narita N, Kato M, Tazoe M, Miyazaki K, Narita M, Okado N. 2002. Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: putative animal models for autism. Pediatr Res 52:576-579.
32. Naruse I, Collins MD, Scott WJ Jr. 1988. Strain differences in the teratogenicity induced by sodium valproate in cultured mouse embryos. Teratology 38:87-96.
33. OECD. 2007. Guideline for the testing of chemials No. 426: developmental neurotoxicity study.
34. Ogawa T, Kuwagata M, Muneoka KT, Shioda S. 2005. Neuropathological examination of fetal rat brain in the 5-bromo-2′-deoxyuridine-induced neurodevelopmental disorder model. Congenit Anom (Kyoto) 45:14-20.
35. Ogawa T, Kuwagata M, Hori Y, Shioda S. 2007. Valproate-induced developmental neurotoxicity is affected by maternal conditions including shipping stress and environmental change during early pregnancy. Toxicol Lett 174:18-24.
36. Rasalam AD, Hailey H, Williams JH etal. 2005. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol 47:551-555.
37. Rogers JM, Mole ML. 1997. Critical periods of sensitivity to the developmental toxicity of inhaled methanol in the CD-1 mouse. Teratology 55:364-372.
38. Schneider T, Przewlocki R. 2005. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 30:80-89.
39. Schneider T, Roman A, Basta-Kaim A etal. 2008. Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid. Psychoneuroendocrinology 33:728-740.
40. Sekerkova G, Ilijic E, Mugnaini E. 2004. Bromodeoxyuridine administered during neurogenesis of the projection neurons causes cerebellar defects in rat. J Comp Neurol 470:221-239.
41. Sills TL, Crawley JN. 1996. Individual differences in sugar consumption predict amphetamine-induced dopamine overflow in nucleus accumbens. Eur J Pharmacol 303:177-181.
42. Soriano E, Del Rio JA. 1991. Simultaneous immunocytochemical visualization of bromodeoxyuridine and neural tissue antigens. J Histochem Cytochem 39:255-263.
43. Stanton ME, Peloso E, Brown KL, Rodier P. 2007. Discrimination learning and reversal of the conditioned eyeblink reflex in a rodent model of autism. Behav Brain Res 176:133-140.
44. Stromland K, Nordin V, Miller M, Akerstrom B, Gillberg C. 1994. Autism in thalidomide embryopathy: a population study. Dev Med Child Neurol 36:351-356.
45. Takahashi T, Goto T, Miyama S, Nowakowski RS, Caviness VS Jr. 1999. Sequence of neuron origin and neocortical laminar fate: relation to cell cycle of origin in the developing murine cerebral wall. J Neurosci 19:10357-10371.
46. Ueno M, Katayama K, Yasoshima A, Nakayama H, Doi K. 2002. 5-Azacytidine (5AzC)-induced histopathological changes in the central nervous system of rat fetuses. Exp Toxicol Pathol 54:91-96.
47. US.EPA. 1998. Health effects guidelines OPPTS 870.6300 developmental neurotoxicity study.
48. Williams G, King J, Cunningham M, Stephan M, Kerr B, Hersh JH. 2001. Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol 43:202-206.
49. Woo GH, Bak EJ, Nakayama H, Doi K. 2006. Molecular mechanisms of hydroxyurea(HU)-induced apoptosis in the mouse fetal brain. Neurotoxicol Teratol 28:125-134.
50. Yamauchi H, Katayama K, Ueno M, Uetsuka K, Nakayama H, Doi K. 2004. Involvement of p53 in 1-beta-d-arabinofuranosylcytosine-induced rat fetal brain lesions. Neurotoxicol Teratol 26:579-586.
51. Young R, Glennon RA. 2008. MDMA (N-methyl-3, 4-methylenedioxyamphetamine) and its stereoisomers: similarities and differences in behavioral effects in an automated activity apparatus in mice. Pharmacol Biochem Behav 88:318-331.